PL396343A1 - Preparat farmaceutyczny zawierający sól wapniową atorwarstatyny, sposób wytwarzania tego preparatu i jego zastosowanie do leczenia hipercholesterolemii i hiperlipidemii - Google Patents

Preparat farmaceutyczny zawierający sól wapniową atorwarstatyny, sposób wytwarzania tego preparatu i jego zastosowanie do leczenia hipercholesterolemii i hiperlipidemii

Info

Publication number: PL396343A1
Authority: PL; Poland
Prior art keywords: atorvastatin; calcium; atorvastatin calcium; calcium salt; amorphous
Prior art date: 2001-03-14

Application number

PL396343A

Other languages

English (en)

Other versions

PL217835B1 (pl

Inventor

Janez Kerc

Mateja Salobir

Sasa Bavec

Original Assignee

Lek Pharmaceuticals D.D.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-14

Filing date

2002-03-13

Publication date

2012-01-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20432850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL396343(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-03-13 Application filed by Lek Pharmaceuticals D.D. filed Critical Lek Pharmaceuticals D.D.

2012-01-16 Publication of PL396343A1 publication Critical patent/PL396343A1/pl

2014-08-29 Publication of PL217835B1 publication Critical patent/PL217835B1/pl

Links

OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical class CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 title abstract 5
208000035150 Hypercholesterolemia Diseases 0.000 title 1
208000031226 Hyperlipidaemia Diseases 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
238000000034 method Methods 0.000 title 1
239000000825 pharmaceutical preparation Substances 0.000 title 1
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 4
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract 4
229960005370 atorvastatin Drugs 0.000 abstract 4
229960001770 atorvastatin calcium Drugs 0.000 abstract 4
239000008194 pharmaceutical composition Substances 0.000 abstract 3
239000000126 substance Substances 0.000 abstract 3
159000000007 calcium salts Chemical class 0.000 abstract 2
229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
239000003529 anticholesteremic agent Substances 0.000 abstract 1
239000002775 capsule Substances 0.000 abstract 1
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000000843 powder Substances 0.000 abstract 1
239000003826 tablet Substances 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Diabetes (AREA)
Obesity (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Pyrrole Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

PL396343A 2001-03-14 2002-03-13 Preparat farmaceutyczny zawierający sól wapniową atorwastatyny, sposób wytwarzania tego preparatu i jego zastosowanie do leczenia hipercholesterolemii i hiperlipidemii PL217835B1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SI200100069A SI20848A (sl)	2001-03-14	2001-03-14	Farmacevtska formulacija, ki vsebuje atorvastatin kalcij

Publications (2)

Publication Number	Publication Date
PL396343A1 true PL396343A1 (pl)	2012-01-16
PL217835B1 PL217835B1 (pl)	2014-08-29

Family

ID=20432850

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL371919A PL211803B1 (pl)	2001-03-14	2002-03-13	Preparat farmaceutyczny zawierający sól wapniową atorwastatyny, sposób wytwarzania tego preparatu i jego zastosowanie do leczenia hipercholesterolemii i hiperlipidemii
PL396343A PL217835B1 (pl)	2001-03-14	2002-03-13	Preparat farmaceutyczny zawierający sól wapniową atorwastatyny, sposób wytwarzania tego preparatu i jego zastosowanie do leczenia hipercholesterolemii i hiperlipidemii

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL371919A PL211803B1 (pl)	2001-03-14	2002-03-13	Preparat farmaceutyczny zawierający sól wapniową atorwastatyny, sposób wytwarzania tego preparatu i jego zastosowanie do leczenia hipercholesterolemii i hiperlipidemii

Country Status (25)

Country	Link
US (1)	US7030151B2 (pl)
EP (2)	EP2263655B1 (pl)
JP (1)	JP4295988B2 (pl)
KR (1)	KR100905730B1 (pl)
CN (1)	CN1630510B (pl)
AT (1)	ATE500818T1 (pl)
BG (1)	BG66339B1 (pl)
BR (1)	BR0207880A (pl)
CA (1)	CA2440331C (pl)
CZ (1)	CZ306128B6 (pl)
DE (1)	DE60239425D1 (pl)
ES (2)	ES2361609T3 (pl)
HR (1)	HRP20030726B1 (pl)
HU (1)	HU230213B1 (pl)
IL (2)	IL157534A0 (pl)
ME (1)	ME00517B (pl)
MX (1)	MXPA03008340A (pl)
PL (2)	PL211803B1 (pl)
RS (2)	RS51746B (pl)
RU (1)	RU2293555C2 (pl)
SI (2)	SI20848A (pl)
SK (1)	SK287925B6 (pl)
UA (1)	UA78201C2 (pl)
WO (1)	WO2002072073A2 (pl)
ZA (1)	ZA200306575B (pl)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE524163T1 (de)	2000-04-10	2011-09-15	Teva Pharma	Stabile pharmazeutische zusammensetzungen enthaltend 7-substituierte-3,5- dihydroxyheptansäuren oder 7-substituierte-3,5- dihydroxyheptensäuren
USRE44578E1 (en)	2000-04-10	2013-11-05	Teva Pharmaceutical Industries, Ltd.	Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
IL156055A0 (en) *	2000-11-30	2003-12-23	Teva Pharma	Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
AU2002224952B2 (en)	2000-12-27	2007-04-05	Teva Pharmaceutical Industries Ltd.	Crystalline forms of atorvastatin
SK16002003A3 (sk)	2001-06-29	2004-12-01	Warner-Lambert Company Llc	Kryštalické formy vápenatej soli (2:1) [R-(R,R)]-2-(4-fluóro- fenyl)-beta,delta-dihydroxy-5-(1-metyletyl)-3-fenyl-4- [(fenylamino)karbonyl]-1H-pyrrol-1-heptánovej kyseliny (atorvastatín)
CA2475722A1 (en) *	2002-02-14	2003-08-21	Romi Barat Singh	Formulations of atorvastatin stabilized with alkali metal additions
AU2003298514A1 (en) *	2002-05-17	2004-05-04	Eisai Co., Ltd.	Methods and compositions using cholinesterase inhibitors
US20070053976A1 (en) *	2002-05-17	2007-03-08	Eisai R & D Management Co., Ltd.	Novel combination of drugs as antidepressant
CA2385529A1 (en) *	2002-05-21	2003-11-21	Bernard Charles Sherman	Stable dosage forms comprising atorvastatin calcium
SI21302A (sl) *	2002-10-11	2004-04-30	LEK farmacevtska dru�ba d.d.	Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
SI21402A (sl)	2003-02-12	2004-08-31	LEK farmacevtska dru�ba d.d.	Obloženi delci in farmacevtske oblike
US7790197B2 (en)	2003-06-09	2010-09-07	Warner-Lambert Company Llc	Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) *	2003-06-12	2005-12-08	Alfred Berchielli	Pharmaceutical compositions of atorvastatin
CA2465693A1 (en) *	2003-06-12	2004-12-12	Warner-Lambert Company Llc	Pharmaceutical compositions of atorvastatin
CA2465565A1 (en) *	2003-06-12	2004-12-12	Warner-Lambert Company Llc	Pharmaceutical compositions of atorvastatin
TR200301614A2 (tr) *	2003-09-26	2005-10-21	Bi̇ofarma İlaç Sanayi̇ Ve Ti̇caret A.Ş.	Atorvastatin kalsiyum tablet formülasyonunun hazırlanması için yeni yöntem
US7875731B2 (en)	2004-05-05	2011-01-25	Pfizer Inc.	Salt forms of [R-(R,R)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid
JP2008506764A (ja)	2004-07-20	2008-03-06	ワーナー−ランバートカンパニーリミテッドライアビリティーカンパニー	［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β、δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸カルシウム塩（２：１）の新規形態
CA2585836A1 (en)	2004-10-28	2006-05-04	Warner-Lambert Company Llc	Process for forming amorphous atorvastatin
WO2006054308A2 (en)	2004-11-22	2006-05-26	Dexcel Pharma Technologies Ltd.	Stable atorvastatin formulations
CA2589537A1 (en) *	2004-12-02	2006-06-08	Stephen Craig Dyar	Pharmaceutical compositions of amorphous atorvastatin and process for preparing same
ES2263370B1 (es) *	2005-02-16	2007-12-01	Ercros Industrial, S.A.	Atorvastatina calcica amorfa estabilizada y procedimiento para su obtencion.
US20080182887A1 (en) *	2005-02-22	2008-07-31	Sun Pharmaceutical Industries Limited	Stable Oral Pharmaceutical Composition
JP5002904B2 (ja) *	2005-04-04	2012-08-15	ブラザー工業株式会社	無線タグ通信装置、その通信方法、及びその通信プログラム
CA2547216A1 (en)	2005-09-21	2007-03-21	Renuka D. Reddy	Process for annealing amorphous atorvastatin
CA2628666A1 (en) *	2005-11-21	2007-05-24	Teva Pharmaceutical Industries Ltd.	Atorvastatin formulation
WO2007057755A1 (en)	2005-11-21	2007-05-24	Warner-Lambert Company Llc	Novel forms of [r-(r,r)]-2-(4-fluorophenyl)-b,b-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-hept anoic acid magnesium
EP1923057A1 (en) *	2005-11-21	2008-05-21	Teva Pharmaceutical Industries Ltd	Atorvastatin pharmaceutical formulation
EP1810667A1 (en) *	2006-01-20	2007-07-25	KRKA, tovarna zdravil, d.d., Novo mesto	Pharmaceutical composition comprising amorphous atorvastatin
US7772273B2 (en) *	2006-02-10	2010-08-10	Lifecycle Pharma A/S	Stabilized atorvastatin
US20080038332A1 (en) *	2006-08-10	2008-02-14	Cai Gu Huang	Stable pharmaceutical formulation comprising atorvastatin calcium
KR101408454B1 (ko) *	2006-12-01	2014-06-17	닛토덴코 가부시키가이샤	도네페질 함유 접착 제제의 착색을 억제하는 방법 및 도네페질의 친척 물질의 생성량을 감소시키는 방법
JP5237112B2 (ja) *	2006-12-01	2013-07-17	日東電工株式会社	経皮吸収製剤
TW200901959A (en)	2007-03-09	2009-01-16	Indigene Pharmaceuticals Inc	Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
US20090226516A1 (en) *	2008-03-04	2009-09-10	Pharma Pass Ii Llc	Sartan compositions
US20090226515A1 (en) *	2008-03-04	2009-09-10	Pharma Pass Ii Llc	Statin compositions
RU2481826C2 (ru) *	2008-05-30	2013-05-20	Нитто Денко Корпорейшн	Содержащий донепезил адгезивный препарат и упаковка для него
RU2483729C2 (ru) *	2008-05-30	2013-06-10	Нитто Денко Корпорейшн	Чрескожно абсорбируемый препарат
US20100151034A1 (en) *	2008-09-30	2010-06-17	Astellas Pharma Inc.	Granular pharmaceutical composition of atorvastatin for oral administration
MY159533A (en) *	2009-01-02	2017-01-13	Univ Putra Malaysia	Porous bioceramic composition for bone repair
JO3635B1 (ar)	2009-05-18	2020-08-27	Millennium Pharm Inc	مركبات صيدلانية صلبة وطرق لانتاجها
RU2404767C1 (ru) *	2009-08-11	2010-11-27	Закрытое Акционерное Общество "БИОКОМ"	Твердая лекарственная форма, обладающая гиполипидемической и гипохолестеринемической активностью, и способ ее получения
KR101248804B1 (ko) *	2010-05-14	2013-03-29	한미사이언스 주식회사	ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제
KR20120011249A (ko)	2010-07-28	2012-02-07	주식회사 경보제약	아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
US20130303519A1 (en)	2012-03-20	2013-11-14	Millennium Pharmaceuticals, Inc.	Methods of treating cancer using aurora kinase inhibitors
CN102755322B (zh) *	2012-07-24	2013-12-11	兆科药业（广州）有限公司	一种乐卡地平和阿托伐他汀复方制剂
WO2014153509A1 (en)	2013-03-22	2014-09-25	Millennium Pharmaceuticals, Inc.	Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
CN104069502B (zh) *	2013-03-29	2018-02-16	北京罗诺强施医药技术研发中心有限公司	复合骨架材料及其药物组合物
CN103705484B (zh) *	2014-01-03	2015-05-20	华北制药集团新药研究开发有限责任公司	一种稳定的阿托伐他汀钙片及其制备方法
CN104013617A (zh) *	2014-05-13	2014-09-03	万特制药(海南)有限公司	一种含有依折麦布和阿托伐他汀钙的组合物及其制备方法
US10413543B2 (en)	2015-09-01	2019-09-17	Sun Pharma Advanced Research Company Ltd.	Stable multiparticulate pharmaceutical composition of rosuvastatin
CN119587702A (zh) *	2018-04-02	2025-03-11	强生化学制药厂股份有限公司	一种可提高口服他汀类药物生体可用率的医药组合物及其用途
CN109044989A (zh) *	2018-10-09	2018-12-21	河南师范大学	一种阿托伐他汀钙胶囊制剂及其制备方法
KR20210098059A (ko)	2020-01-31	2021-08-10	주식회사 일원바이오	양춘사 추출물을 유효성분으로 함유하는 고지혈증 또는 동맥경화의 예방, 개선 또는 치료용 조성물
KR102643099B1 (ko)	2020-01-31	2024-03-05	주식회사 일원바이오	양춘사 및 백출 복합 추출물을 유효성분으로 함유하는 고지혈증 또는 동맥경화의 예방, 개선 또는 치료용 조성물
AU2021273936A1 (en) *	2020-05-22	2022-12-08	Durect Corporation	Treatment of non-alcoholic steatohepatitis (NASH)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5003080A (en)	1988-02-22	1991-03-26	Warner-Lambert Company	Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5149837A (en)	1988-02-22	1992-09-22	Warner-Lambert Company	Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en)	1988-02-22	1992-06-23	Warner-Lambert Company	Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en)	1988-02-22	1993-09-14	Warner-Lambert Company	Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en)	1989-02-01	1992-03-17	Warner-Lambert Company	Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en)	1988-02-22	1993-06-01	Warner-Lambert Co.	Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) *	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5248793A (en)	1990-10-17	1993-09-28	Warner-Lambert Company	Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en)	1990-10-17	1992-04-07	Warner-Lambert Company	Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en)	1991-10-11	1992-10-13	Warner-Lambert Company	Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
JP3254219B2 (ja) *	1993-01-19	2002-02-04	ワーナー−ランバート・コンパニー	安定な経口用のｃｉ−９８１製剤およびその製法
FR2700452B1 (fr)	1993-01-20	1995-03-24	Mgb	Structure transformable de réception du corps d'une personne, par exemple siège-berceau pour enfant.
US5298627A (en)	1993-03-03	1994-03-29	Warner-Lambert Company	Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
HRP960313B1 (en)	1995-07-17	2002-08-31	Warner Lambert Co	Form iii crystalline (r- (r, r)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
HRP960312B1 (en) *	1995-07-17	2001-10-31	Warner Lambert Co	NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R, R)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
KR100431038B1 (ko) *	1995-07-17	2004-05-12	워너-램버트 캄파니 엘엘씨	결정질[ｒ-(ｒ,ｒ)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1ｈ-피롤-1-헵탄산 헤미 칼슘염 (아토르바스타틴)
US5874029A (en)	1996-10-09	1999-02-23	The University Of Kansas	Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US6372246B1 (en)	1998-12-16	2002-04-16	Ortho-Mcneil Pharmaceutical, Inc.	Polyethylene glycol coating for electrostatic dry deposition of pharmaceuticals
SI20109A (sl) *	1998-12-16	2000-06-30	LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.	Stabilna farmacevtska formulacija
US6696086B1 (en) *	1999-09-10	2004-02-24	Lek Pharmaceuticals D.D.	Solid pharmaceutical formulation containing lovastatin and simvastatin, respectively, and its preparation
SI20425A (sl)	1999-12-10	2001-06-30	LEK tovarna farmacevtskih in kemi�nih izdelkov d.d.	Priprava amorfnega atorvastatina
ATE524163T1 (de) *	2000-04-10	2011-09-15	Teva Pharma	Stabile pharmazeutische zusammensetzungen enthaltend 7-substituierte-3,5- dihydroxyheptansäuren oder 7-substituierte-3,5- dihydroxyheptensäuren
HRP20020950A2 (en) *	2000-06-09	2004-12-31	Lek Tovarna Farmacevtskih	Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
US6806290B2 (en) *	2000-06-09	2004-10-19	Lek Pharmaceuticals D.D.	Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same

2001
- 2001-03-14 SI SI200100069A patent/SI20848A/sl not_active IP Right Cessation
2002
- 2002-02-13 IL IL15753402A patent/IL157534A0/xx unknown
- 2002-03-13 MX MXPA03008340A patent/MXPA03008340A/es active IP Right Grant
- 2002-03-13 DE DE60239425T patent/DE60239425D1/de not_active Expired - Lifetime
- 2002-03-13 PL PL371919A patent/PL211803B1/pl unknown
- 2002-03-13 PL PL396343A patent/PL217835B1/pl unknown
- 2002-03-13 AT AT02702654T patent/ATE500818T1/de not_active IP Right Cessation
- 2002-03-13 CZ CZ2003-2469A patent/CZ306128B6/cs not_active IP Right Cessation
- 2002-03-13 KR KR1020037011535A patent/KR100905730B1/ko not_active Expired - Lifetime
- 2002-03-13 SI SI200230945T patent/SI1499297T1/sl unknown
- 2002-03-13 UA UA2003098317A patent/UA78201C2/xx unknown
- 2002-03-13 ES ES02702654T patent/ES2361609T3/es not_active Expired - Lifetime
- 2002-03-13 CA CA002440331A patent/CA2440331C/en not_active Expired - Lifetime
- 2002-03-13 EP EP10183122.0A patent/EP2263655B1/en not_active Expired - Lifetime
- 2002-03-13 SK SK1136-2003A patent/SK287925B6/sk unknown
- 2002-03-13 RS YU69603A patent/RS51746B/sr unknown
- 2002-03-13 ME MEP-2008-845A patent/ME00517B/me unknown
- 2002-03-13 BR BR0207880-5A patent/BR0207880A/pt not_active Application Discontinuation
- 2002-03-13 JP JP2002571032A patent/JP4295988B2/ja not_active Expired - Lifetime
- 2002-03-13 HR HRP20030726AA patent/HRP20030726B1/hr not_active IP Right Cessation
- 2002-03-13 ES ES10183122T patent/ES2417881T3/es not_active Expired - Lifetime
- 2002-03-13 RS RS20110313A patent/RS55021B1/sr unknown
- 2002-03-13 CN CN028064739A patent/CN1630510B/zh not_active Expired - Lifetime
- 2002-03-13 US US10/471,906 patent/US7030151B2/en not_active Expired - Lifetime
- 2002-03-13 EP EP02702654A patent/EP1499297B1/en not_active Expired - Lifetime
- 2002-03-13 RU RU2003130378/15A patent/RU2293555C2/ru active
- 2002-03-13 WO PCT/IB2002/000736 patent/WO2002072073A2/en not_active Ceased
- 2002-03-13 HU HU0303434A patent/HU230213B1/hu unknown
2003
- 2003-08-21 IL IL157534A patent/IL157534A/en active IP Right Grant
- 2003-08-22 ZA ZA200306575A patent/ZA200306575B/en unknown
- 2003-09-12 BG BG108175A patent/BG66339B1/bg unknown

Also Published As

Publication number	Publication date
HUP0303434A3 (en)	2011-09-28
YU69603A (sh)	2006-05-25
CA2440331A1 (en)	2002-09-19
ME00517B (me)	2011-10-10
RU2293555C2 (ru)	2007-02-20
EP2263655B1 (en)	2013-04-24
ATE500818T1 (de)	2011-03-15
KR100905730B1 (ko)	2009-07-01
RU2003130378A (ru)	2005-04-10
BG108175A (en)	2004-09-30
US7030151B2 (en)	2006-04-18
CZ306128B6 (cs)	2016-08-17
RS51746B (sr)	2011-10-31
CZ20032469A3 (cs)	2004-09-15
JP2004533999A (ja)	2004-11-11
BG66339B1 (bg)	2013-07-31
ZA200306575B (en)	2004-09-30
DE60239425D1 (de)	2011-04-21
KR20040025901A (ko)	2004-03-26
UA78201C2 (en)	2007-03-15
SI1499297T1 (sl)	2011-07-29
HUP0303434A2 (hu)	2004-01-28
RS20110313A (sr)	2011-10-31
RS55021B1 (sr)	2016-11-30
ES2361609T3 (es)	2011-06-20
WO2002072073A2 (en)	2002-09-19
PL211803B1 (pl)	2012-06-29
JP4295988B2 (ja)	2009-07-15
IL157534A (en)	2009-12-24
HRP20030726A2 (en)	2005-04-30
CA2440331C (en)	2008-05-06
HU230213B1 (hu)	2015-10-28
ES2417881T3 (es)	2013-08-09
US20040138290A1 (en)	2004-07-15
SI20848A (sl)	2002-10-31
EP2263655A1 (en)	2010-12-22
CN1630510A (zh)	2005-06-22
SK287925B6 (sk)	2012-04-03
CN1630510B (zh)	2012-04-04
PL217835B1 (pl)	2014-08-29
WO2002072073A3 (en)	2004-05-13
BR0207880A (pt)	2004-03-02
HRP20030726B1 (hr)	2013-04-30
PL371919A1 (pl)	2005-07-11
MXPA03008340A (es)	2004-10-15
EP1499297A2 (en)	2005-01-26
EP1499297B1 (en)	2011-03-09
IL157534A0 (en)	2004-03-28
SK11362003A3 (sk)	2004-02-03

Publication	Publication Date	Title
SI1499297T1 (sl)	2011-07-29	Farmacevtska oblika, ki vsebuje atorvastatin kalcij
YU56803A (sh)	2006-05-25	Pripremanje nekristalinskog atorvastatin-kalcijuma
HUP9901687A2 (hu)	1999-10-28	Kristályos (III) formájú (R-(R,R)-2-(4-fluor-fenil)-béta,delta-dihidroxi-5-(1-metil-etil)-3-fenil-4-((fenil-amino)-karbonil)-1H-pirrol-1-heptánsav hemi kálcium-só (Atorvastatin) és ezt a vegyületet tartalmazó gyógyszerkészítmények
GEP20053546B (en)	2005-06-10	Crystalline Forms of 'R-(R,R)!-2-(4- Fluorophenyl)-Beta, Delta-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-'Phenylamino) Carbonyl!-1H-Pyrrole-1-Heptanoic Acid Calcium Salt (2:1) (Atorvastatin)
HRP20020429A2 (en)	2004-04-30	Polymorphic form of atorvastatin calcium
HUP0401569A2 (hu)	2004-12-28	Amlodipint és atorvastatint tartalmazó gyógyászati készítmények és eljárás az előállításukra
ATE158504T1 (de)	1997-10-15	Brausemischungen enthaltend ibuprofen und verfahren
BG106389A (en)	2002-09-30	Crystals of the sodium salt of pravastatin
DE60025503D1 (de)	2006-04-06	Pharmazeutische Zusammensetzungen, die Faropenem Natrium und eine Diamineacetat Verbindung zur Verbesserung der Magen-Darm Trakt Absorption enthalten
WO2005105738A3 (en)	2006-03-30	Salt forms of atorvastatin
ATE240098T1 (de)	2003-05-15	Stoffe zur hemmung der bildung des pterygiums und seines postoperative wiederauftretens
CA2373962A1 (en)	2000-11-30	Immediate release medicinal compositions for oral use
NO20075721L (no)	2008-01-04	New crystalline atorvastatin hemicalcium salt polymorph form
AU2003256108A1 (en)	2004-03-11	Organic acid salt of amlodipine
TW200738624A (en)	2007-10-16	Novel forms of [R-(R,R)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium
WO2005030183A2 (en)	2005-04-07	A method for the preparation of atorvastatin calcium tablets
WO2003097039A1 (en)	2003-11-27	Stable dosage forms comprising atorvastatin calcium
CY1110814T1 (el)	2015-06-10	Νεα υποκατεστημενα αρυλοεξαδιενικα οξεα και εστερες αυτων τα οποια μπορουν να χρησιμοποιηθουν για την αγωγη και προληψη του διαβητη, δυσλιπιδαιμιας και αθηροσκληρωσης, φαρμακευτικες συνθεσεις που τα περιλαμβανουν και διεργασιες για την παρασκευη αυτων
JP2003095939A (ja)	2003-04-03	安定なプラバスタチンナトリウム錠
UA93202C2 (ru)	2011-01-25	Полиморфная форма кристаллической гемикальциевой соли аторвастатина
WO2008096377A2 (en)	2008-08-14	Stable atorvastatin formulations
CA2521833A1 (en)	2003-01-16	Crystalline forms of [r-(r,r)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)